Cerebrovascular Angiotensin AT1 Receptor Regulation in Cerebral Ischemia

Trends in Cardiovascular Medicine

Volumn 18, Issue 3, 2008, Pages 98-103

  Edvinsson, Lars ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR AT1; DIPEPTIDYL CARBOXYPEPTIDASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BRAIN ARTERY; BRAIN CIRCULATION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; HUMAN; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STROKE; ANIMAL; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; UPREGULATION; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; ENDOTHELIUM, VASCULAR; HUMANS; RECEPTOR, ANGIOTENSIN, TYPE 1; UP-REGULATION;

EID: 43049100001     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2008.01.005     Document Type: Review

References (41)

1. Barry D.I., Jarden J.O., Paulson O.B., et al. Cerebrovascular aspects of converting-enzyme inhibition I: effects of intravenous captopril in spontaneously hyperftensive and normotensive rats. J Hypertens 2 (1984) 589-597
2. Barry D.I., Paulson O.B., Jarden J.O., et al. Effects of captopril on cerebral blood flow in normotensive and hypertensive rats. Am J Med 76 (1984) 79-85
3. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
4. Chrysant S.G. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. J Hum Hypertens 19 (2005) 923-931
5. Cui T., Nakagami H., Iwai M., et al. ATRAP, novel AT1 receptor associated protein, enhances internalization of AT1 receptor and inhibits vascular smooth muscle cell growth. Biochem Biophys Res Commun 279 (2000) 938-941
6. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
7. Dai W.J., Funk A., Herdegen T., et al. Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 30 (1999) 2391-2398 discussion 2398-2399
8. Edvinsson L., and Krause D.N. Cerebral blood flow and metabolism (2002), Lippincott Williams Wilkins, Philadelphia
9. Engelhorn T., Goerike S., Doerfler A., et al. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab 24 (2004) 467-474
10. Fournier A., Messerli F.H., Achard J.M., and Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 43 (2004) 1343-1347
11. Groth W., Blume A., Gohlke P., et al. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. J Hypertens 21 (2003) 2175-2182
12. Guo D.F., Chenier I., Tardif V., et al. Type 1 angiotensin II receptor-associated protein ARAP1 binds and recycles the receptor to the plasma membrane. Biochem Biophys Res Commun 310 (2003) 1254-1265
13. Hosomi N., Mizushige K., Kitadai M., et al. Induced hypertension treatment to improve cerebral ischemic injury after transient forebrain ischemia. Brain Res 835 (1999) 188-196
14. Hosomi N., Nishiyama A., Ban C.R., et al. Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience 134 (2005) 225-231
15. Ito T., Yamakawa H., Bregonzio C., et al. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 33 (2002) 2297-2303
16. Iwai M., Liu H.W., Chen R., et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 110 (2004) 843-848
17. Jarden J.O., Barry D.I., Juhler M., et al. Cerebrovascular aspects of converting-enzyme inhibition II: blood-brain barrier permeability and effect of intracerebroventricular administration of captopril. J Hypertens 2 (1984) 599-604
18. Jarden J.O., Barry D.I., Strandgaard S., et al. Cerebrovascular effects of the converting enzyme inhibitor captopril. J Hypertens Suppl 1 (1983) 126-128
19. Li J., Culman J., Hortnagl H., et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. Faseb J 19 (2005) 617-619
20. Lou M., Blume A., Zhao Y., et al. Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat. J Cereb Blood Flow Metab 24 (2004) 536-547
21. Nakayama I., Kawahara Y., Tsuda T., et al. Angiotensin II inhibits cytokine-stimulated inducible nitric oxide synthase expression in vascular smooth muscle cells. J Biol Chem 269 (1994) 11628-11633
22. Naveri L., Stromberg C., and Saavedra J.M. Angiotensin II AT2 receptor stimulation extends the upper limit of cerebral blood flow autoregulation: agonist effects of CGP 42112 and PD 123319. J Cereb Blood Flow Metab 14 (1994) 38-44
23. Nickenig G., Strehlow K., Baumer A.T., et al. Negative feedback regulation of reactive oxygen species on AT1 receptor gene expression. Br J Pharmacol 131 (2000) 795-803
24. Nishimura Y., Ito T., Hoe K., and Saavedra J.M. Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors. Brain Res 871 (2000) 29-38
25. Nishimura Y., Ito T., and Saavedra J.M. Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 31 (2000) 2478-2486
26. O'Collins V.E., Macleod M.R., Donnan G.A., et al. 1,026 experimental treatments in acute stroke. Ann Neurol 59 (2006) 467-477
27. Parmentier S., Bohme G.A., Lerouet D., et al. Selective inhibition of inducible nitric oxide synthase prevents ischaemic brain injury. Br J Pharmacol 127 (1999) 546-552
28. Paulson O.B., Strandgaard S., and Edvinsson L. Cerebral autoregulation. Cerebrovasc Brain Metab Rev 2 (1990) 161-192
29. Rajagopalan B., Raine A.E., Cooper R., and Ledingham J.G. Changes in cerebral blood flow in patients with severe congestive cardiac failure before and after captopril treatment. Am J Med 76 (1984) 86-90
30. Schrader J., Luders S., Kulschewski A., et al. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34 (2003) 1699-1703
31. Schrader J., Luders S., Kulschewski A., et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36 (2005) 1218-1226
32. Stenman E., and Edvinsson L. Cerebral ischemia enhances vascular angiotensin AT1 receptor-mediated contraction in rats. Stroke 35 (2004) 970-974
33. Stenman E., Jamali R., Henriksson M., et al. Cooperative effect of angiotensin AT(1) and endothelin ET(A) receptor antagonism limits the brain damage after ischemic stroke in rat. Eur J Pharmacol 570 (2007) 142-148
34. Strandgaard S., Olesen J., Skinhoj E., and Lassen N.A. Autoregulation of brain circulation in severe arterial hypertension. Br Med J 1 (1973) 507-510
35. Sugawara T., Kinouchi H., Oda M., et al. Candesartan reduces superoxide production after global cerebral ischemia. Neuroreport 16 (2005) 325-328
36. Tuor U.I., Kondysar M.H., and Harding R.K. Effect of angiotensin II and peptide YY on cerebral and circumventricular blood flow. Peptides 9 (1988) 141-149
37. Vacher E., Richer C., and Giudicelli J.F. Effects of losartan on cerebral arteries in stroke-prone spontaneously hypertensive rats. J Hypertens 14 (1996) 1341-1348
38. Wackenfors A., Vikman P., Nilsson E., et al. Angiotensin II-induced vasodilatation in cerebral arteries is mediated by endothelium-derived hyperpolarising factor. Eur J Pharmacol 531 (2006) 259-263
39. Vikman P., and Edvinsson L. Gene expression profiling in the human middle cerebral artery after cerebral ischemia. Eur J Neurol 13 (2006) 1324-1332
40. Vincent J.M., Kwan Y.W., Chan S.L., et al. Constrictor and dilator effects of angiotensin II on cerebral arterioles. Stroke 36 (2005) 2691-2695
41. Zhou J., Ando H., Macova M., et al. Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J Cereb Blood Flow Metab 25 (2005) 878-886